CytoMed Therapeutics Ltd(GDTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.26 | Insider Own | 56.1% | Shs Outstand | 11.8M | Perf Week | 2.71% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | 1.72% | Shs Float | 5.2M | Perf Month | -9% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 0.1% | Short Float | 0.12% | Perf Quarter | -8.08% |
| Income | -0.00B | P/S | 43.08 | EPS this Y | - | Inst Trans | -5.26% | Short Ratio | 0.08 | Perf Half Y | -12.5% |
| Sales | 0.00B | P/B | 2.12 | EPS next 5Y | - | ROA | -44.76% | Short Interest | 0.01M | Perf YTD | -31.84% |
| Book/sh | 0.43 | P/C | 6.61 | EPS past 3/5Y | -8.01% -226.97% | ROE | -52.16% | 52W High | -75.27% ($3.68) | Perf Year | -55.61% |
| Cash/sh | 0.14 | P/FCF | - | Sales past 3/5Y | - | ROIC | -56.14% | 52W Low | 33.8% ($0.68) | Perf 3Y | -73.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -59.79% | Gross Margin | -278.46% | Volatility(W/M) | 14.43% 11.68% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 39.04 | Sales Y/Y TTM | 373.88% | Oper. Margin | -1434.5% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.17 | EPS Q/Q | -22.4% | Profit Margin | -1224.43% | RSI (14) | 51.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.17 | Sales Q/Q | 149.21% | SMA20 | 1.64% ($0.9) | Beta | 0.05 | Target Price | $4.16 |
| Payout | - | Debt/Eq | 0.07 | Earnings | - | SMA50 | 0.01% ($0.91) | Rel Volume | 0.12 | Prev Close | $0.91 |
| Employees | 42 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | - | SMA200 | -14.72% ($1.07) | Avg Volume(3M) | 0.08M | Price | $0.91 |
| IPO | 2023/4/14 | Option/Short | No/Yes | Trades | 63 | Volume | 9,675 | Change | - |
Company
GDTC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧪 Cytomed Therapeutics () is a Singapore-based clinical-stage biotech company developing gamma-delta (γδ) T cell-based allogeneic ("off-the-shelf") cellular immunotherapies. It is clinically advancing its proprietary CAR-γδ T cell therapy CTM-N2D and its non-genetically-modified γδ T cell therapy CTM-GDT for both solid tumors and hematologic cancers, and has recently expanded its pipeline through the acquisition of TC BioPharm's gamma-delta T cell technology TCB-002 — making it a small-cap Asian biotech play.
Over the past 1 year, on the lower side
75% below its 1-year high.
GDTC has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -73.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.1%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $11M.
GDTC $11M PER -
VRTX $131B PER 30.0
REGN $83B PER 19.8
MRNA $73B PER -
FAQ
What kind of company is GDTC?
GDTC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GDTC?
The market cap of GDTC is approximately $11M, ranking 5,484 within its sector.
What is the 52-week high and low for GDTC?
GDTC has recorded a 52-week high of $3.68 and a low of $0.68.
